{"id":233890,"date":"2026-03-23T11:06:20","date_gmt":"2026-03-23T16:06:20","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/03\/catch-bond-engineering-turbocharge-t-cells-to-attack-prostate-cancer"},"modified":"2026-03-23T11:06:20","modified_gmt":"2026-03-23T16:06:20","slug":"catch-bond-engineering-turbocharge-t-cells-to-attack-prostate-cancer","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/03\/catch-bond-engineering-turbocharge-t-cells-to-attack-prostate-cancer","title":{"rendered":"Catch-bond engineering \u201cturbocharge\u201d T cells to attack prostate cancer"},"content":{"rendered":"

<\/a><\/p>\n

T cells are a powerful weapon in the fight against cancer, forming the basis of treatments such as CAR-T cell therapy and checkpoint inhibitors. This research centers on another type of immunotherapy approach called T cell receptor (TCR) therapy, which engineers T cells to recognize specific proteins on cancer cells, allowing for highly targeted attacks.<\/p>\n

Many of these proteins, however, are \u201cself-antigens,\u201d or molecules normally found in the body. To prevent these T cells from attacking healthy tissue, the immune system naturally eliminates the strongest cancer-fighting T cells during development. This leaves behind weaker T cell receptors that may struggle to recognize and destroy tumors, particularly those that have learned to evade immune defenses.<\/p>\n

To overcome this challenge, researchers focused on fine-tuning naturally occurring T cell receptors to strengthen their ability to recognize a common prostate cancer protein called prostatic acid phosphatase (PAP), which is commonly expressed on prostate tissue and prostate tumors. The team identified a naturally weak TCR, known as TCR156, that could detect PAP but was not strong enough to effectively kill cancer cells.<\/p>\n

Using a novel technique called catch bond engineering, a concept developed by the Lab, the researchers \u201cturbocharged\u201d the T cells. In the body, T cells form brief, mechanical bonds with their targets, known as catch bonds, which help them sense and respond to threats. By altering just one or two amino acids in the T cell receptor, the scientists were able to strengthen these bonds while preserving the T cells\u2019 natural ability to recognize their specific target.<\/p>\n

Multiple engineered versions of TCR156 were created and tested. Two candidates proved to be the most effective. These engineered T cells were analyzed for their ability to recognize tumors, release cancer-killing molecules, proliferate, and resist exhaustion. Advanced imaging, single-cell RNA sequencing, and structural analyses were used to confirm that the modifications improved T cell function while maintaining precision and avoiding off-target effects.<\/p>\n

Structural and computer modeling studies showed that the catch bond mutations did not change the overall TCR shape but primed it to form a new interaction with PAP when the T cell engaged the tumor, explaining how the engineered T cells could remain highly specific while dramatically boosting their cancer-killing ability.<\/p>\n

The researchers found that a single amino acid change created a catch bond hotspot that significantly enhanced T cell function. This change did not directly contact the cancer protein until the T cell engaged dynamically, demonstrating that a tiny modification can have a major effect. Most importantly, the modifications did not make the cells attack healthy tissue.<\/p>\n

Continue reading \u201cCatch-bond engineering \u201cturbocharge\u201d T cells to attack prostate cancer\u201d | ><\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

T cells are a powerful weapon in the fight against cancer, forming the basis of treatments such as CAR-T cell therapy and checkpoint inhibitors. This research centers on another type of immunotherapy approach called T cell receptor (TCR) therapy, which engineers T cells to recognize specific proteins on cancer cells, allowing for highly targeted attacks. [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1523,38],"tags":[],"class_list":["post-233890","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-computing","category-engineering"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/233890","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=233890"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/233890\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=233890"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=233890"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=233890"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}